Welcome to SAMHSA's Publications site. In the future, you may be asked to respond to a CAPTCHA to access the site for added security.
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.
This toolkit offers strategies to health care providers, communities, and local governments for developing practices and policies to help prevent opioid-related overdoses and deaths. Access reports for community members, prescribers, patients and families, and those recovering from opioid overdose.
Equipa a los proveedores de atención médica, las comunidades y los gobiernos locales con materiales para desarrollar prácticas y políticas para ayudar a prevenir las sobredosis y las muertes relacionadas con los opioides. Aborda diferentes asuntos de interés para los proveedores de atención médica, personal de primeros auxilios, los proveedores de tratamientos y los que están recuperándose de sobredosis de opioides. Actualizada en el 2018.
This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.
This guide explains prescription drug monitoring programs (PDMPs), and how they can enhance clinical decision making. The guide also explains how PDMP improves patient safety, while helping to decrease prescription drug misuse and unintentional overdose deaths.
This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.
This advisory answers questions about the seriousness of prescription drug misuse. It explains how people become dependent on prescription drugs, and treatment options. The advisory also offers necessary treatment resources for professionals.
Millions of Americans have a substance use disorder. Find a treatment facility near you.
Free and confidential support for people in distress, 24/7.
Find treatment facilities confidentially and anonymously, 24/7.
Treatment referral and information, 24/7.